The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk $NOVO B (+4,52%)
$LLY (+8,82%) Eli Lilly's weight-
loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing facilities.
https://www.tradingview.com/news/reuters.com,2026:newsml_L4N41D206:0-us-fda-proposes-curbs-on-mass-compounding-of-novo-lilly-s-weight-loss-drugs/